PMID- 33325020
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20220531
IS  - 1833-3516 (Print)
IS  - 2209-1491 (Electronic)
IS  - 1833-3516 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Dec 20
TI  - Hyperbaric oxygen but not hyperbaric air increases insulin sensitivity in men 
      with type 2 diabetes mellitus.
PG  - 386-390
LID - 10.28920/dhm50.4.386-390 [doi]
AB  - INTRODUCTION: We have previously shown that hyperbaric oxygen treatment (HBOT) 
      increased insulin sensitivity in men who were obese or overweight, both with and 
      without type 2 diabetes. The aim of this study was to test whether this 
      insulin-sensitising effect is seen in hyperbaric air (HA). METHODS: Men with type 
      2 diabetes who were obese or overweight were randomised to two groups: HBOT (n = 
      13) or HA (n = 11). A hyperinsulinaemic euglycaemic glucose clamp (80 
      mU.m(-2).min(-1)) was performed at baseline and during hyperbaric intervention. 
      Both groups were compressed to 203 kPa (two atmospheres absolute) for 90 minutes 
      followed by a linear 30-minute decompression. The HBOT group breathed oxygen via 
      a hood while the HA group breathed chamber air. Insulin sensitivity was assessed 
      from the glucose infusion rate (GIR) during the last 30 minutes in the hyperbaric 
      chamber (SS1) and the first 30 minutes after exit (SS2). Data were analysed for 
      within-group effect by paired student t-test and between-group effect by one-way 
      ANOVA. RESULTS: HBOT increased GIR by a mean 26% at SS1 (P = 0.04) and 23% at SS2 
      (P = 0.018). There was no significant change in GIR during or after HA. A 
      between-group effect was evident for the change in GIR at SS1 in HBOT vs HA (P = 
      0.036). CONCLUSIONS: The pathway by which insulin sensitivity is increased in men 
      with type 2 diabetes requires the high oxygen partial pressures of HBOT and 
      should be further investigated. Insulin sensitivity was not changed in hyperbaric 
      air.
CI  - Copyright: This article is the copyright of the authors who grant Diving and 
      Hyperbaric Medicine a non-exclusive licence to publish the article in electronic 
      and other forms.
FAU - Wilkinson, David C
AU  - Wilkinson DC
AD  - Hyperbaric Medicine Unit, Royal Adelaide Hospital, Adelaide, Australia.
AD  - Adelaide Medical School, The University of Adelaide, Adelaide, Australia.
AD  - Corresponding author: Dr David Wilkinson, Hyperbaric Medicine Unit, Royal 
      Adelaide Hospital, Port Road, Adelaide SA 5000, Australia, 
      david.wilkinson@sa.gov.au.
FAU - Chapman, Ian M
AU  - Chapman IM
AD  - Adelaide Medical School, The University of Adelaide, Adelaide, Australia.
FAU - Heilbronn, Leonie K
AU  - Heilbronn LK
AD  - Adelaide Medical School, The University of Adelaide, Adelaide, Australia.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Australia
TA  - Diving Hyperb Med
JT  - Diving and hyperbaric medicine
JID - 101282742
RN  - 0 (Insulin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Humans
MH  - *Hyperbaric Oxygenation
MH  - Insulin
MH  - *Insulin Resistance
MH  - Male
MH  - Oxygen
PMC - PMC8026233
OTO - NOTNLM
OT  - Blood sugar level
OT  - Diabetes
OT  - Endocrinology
OT  - Hyperbaric research
OT  - Metabolism
COIS- Conflict of interest and funding: This study was funded by the Royal Adelaide 
      Hospital Research Committee. No conflicts of interest were declared.
EDAT- 2020/12/17 06:00
MHDA- 2020/12/18 06:00
PMCR- 2021/12/20
CRDT- 2020/12/16 05:40
PHST- 2020/06/11 00:00 [received]
PHST- 2020/08/22 00:00 [accepted]
PHST- 2020/12/16 05:40 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2021/12/20 00:00 [pmc-release]
AID - 10.28920/dhm50.4.386-390 [doi]
PST - ppublish
SO  - Diving Hyperb Med. 2020 Dec 20;50(4):386-390. doi: 10.28920/dhm50.4.386-390.